Please use this identifier to cite or link to this item:http://hdl.handle.net/20.500.12105/9755
Title
Alpha-1 antitrypsin deficiency: outstanding questions and future directions
Author(s)
Torres-Durán, María | Lopez-Campos, José Luis | Barrecheguren, Miriam | Miravitlles, Marc | Martinez-Delgado, Beatriz ISCIII | Castillo, Silvia | Escribano, Amparo | Baloira, Adolfo | Navarro-Garcia, María Mercedes | Pellicer, Daniel | Bañuls, Lucía | Magallón, María | Casas, Francisco | Dasí, Francisco
Date issued
2018
Citation
Orphanet J Rare Dis. 2018 Jul 11;13(1):114.
Language
Inglés
Document type
journal article
Abstract
BACKGROUND: Alpha-1 antitrypsin deficiency (AATD) is a rare hereditary condition that leads to decreased circulating alpha-1 antitrypsin (AAT) levels, significantly increasing the risk of serious lung and/or liver disease in children and adults, in which some aspects remain unresolved. METHODS: In this review, we summarise and update current knowledge on alpha-1 antitrypsin deficiency in order to identify and discuss areas of controversy and formulate questions that need further research. RESULTS: 1) AATD is a highly underdiagnosed condition. Over 120,000 European individuals are estimated to have severe AATD and more than 90% of them are underdiagnosed. CONCLUSIONS: 2) Several clinical and etiological aspects of the disease are yet to be resolved. New strategies for early detection and biomarkers for patient outcome prediction are needed to reduce morbidity and mortality in these patients; 3) Augmentation therapy is the only specific approved therapy that has shown clinical efficacy in delaying the progression of emphysema. Regrettably, some countries reject registration and reimbursement for this treatment because of the lack of larger randomised, placebo-controlled trials. 4) Alternative strategies are currently being investigated, including the use of gene therapy or induced pluripotent stem cells, and non-augmentation strategies to prevent AAT polymerisation inside hepatocytes.
Subject
Alpha-1 antitrypsin | Alpha-1 antitrypsin deficiency | Augmentation therapy | COPD | Cirrhosis | Panniculitis | Rare respiratory diseases | SERPINA1 | Vasculitis
MESH
Animals | Fibrosis | Humans | Panniculitis | Pulmonary Disease, Chronic Obstructive | Vasculitis | alpha 1-Antitrypsin | alpha 1-Antitrypsin Deficiency
Online version
DOI
Collections
- Investigación > ISCIII > Instituto de Investigación de Enfermedades Raras (IIER)
- Investigación > IIS > INCLIVA - Instituto de Investigación Sanitaria Fundación para la Investigación del Hospital Clínico de Valencia (C. Valenciana)
- Investigación > IIS > IBIS - Instituto de Biomedicina de Sevilla (Andalucía)
- Investigación > IIS > IISGS - Instituto de Investigación Sanitaria Galicia Sur (Galicia)